Paris, May16, 2011 – BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that Loramyc® has been launched in Germany by its European partner Therabel. Therabel has created a fully dedicated team and has also entered into a co-promotion agreement with Hikma Pharma GmbH, a leading specialty pharmaceutical group focused on branded and generic products in Oncology.
“These significant efforts mark a positive and concrete step forward of our European partnership with Therabel,” stated Dominique Costantini, CEO of BioAlliance Pharma. “We are very confident in Therabel and Hikma teams’ involvement and know-how to ensure Loramyc® success in Germany.”
“Our team is committed to create an hospital presence through Loramyc® with oncologists and HIV specialists and we are delighted to deepen this presence further with the experience and support of the Hikma sales force directed to private oncologists and haematologists,” said Jean-Michel Robert, President of Therabel Strategic Committee.
Loramyc® is a mucoadhesive gingival tablet containing miconazole administered once-a-day over 7 to 14 days and is indicated for the treatment of oropharyngeal candidiasis in immune compromised patients.
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.
About BioAlliance Pharma
Dedicated to Specialty Pharma and Orphan products in cancer treatment and in supportive care, with a focus on drug resistance, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Specialty Pharma products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US)
Setofilm® (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU
Sitavir® (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Phase II results on survival
Clonidine LauriadTM (chemoradiation therapy induced mucositis in H&N cancer): Phase II on going
Biotherapy AMEP® (metastatic invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
Judith Greciet, COO
Tel +33 1 45 58 70 61
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59